Brittany Swift
Acute Care · Rochester, NYNPI 1588064083
Payments from drug & device makers
Across 149 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$193
- Astellas Pharma US Inc$150
- Bayer$147
- Abbott$117
- Amarin Pharma, Inc.$101
- plus $577 from 15 others
What the payments were for
- Food & beverage$2,18995%
- Education$1135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $1,016 |
| Novo Nordisk | 11 | $193 |
| Astellas Pharma US Inc | 9 | $150 |
| Bayer | 8 | $147 |
| Abbott | 6 | $117 |
| Amarin Pharma, Inc. | 5 | $101 |
| Lilly USA, LLC | 6 | $98 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $86 |
| Pfizer | 4 | $73 |
| Amgen | 2 | $50 |
| GSK | 2 | $38 |
| AstraZeneca | 3 | $37 |
| Biogen | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$2,301 in reported general payments places this provider in the 90th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 30 | $16,376 |
| SynthroidLevothyroxine Sodium | 14 | $1,500 |
| Levothyroxine Sodium | 79 | $1,127 |
| Omeprazole | 34 | $891 |
| Metoprolol Succinate | 14 | $643 |
| Icosapent Ethyl | 11 | $446 |
| Atorvastatin Calcium | 39 | $416 |
| Rosuvastatin Calcium | 29 | $391 |
| Telmisartan | 11 | $364 |
| Gabapentin | 29 | $357 |
| Pantoprazole Sodium | 17 | $325 |
| Sucralfate | 13 | $270 |
| Famotidine | 14 | $217 |
| Pravastatin Sodium | 14 | $145 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $1,016 | $1,50014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 980 acute care providers in New York.
Other acute care in Rochester
- Bettina BroughtonRochester$7K
- Ann FrickeRochester$6K
- Marie BianchiRochester$3K
- Daniel VerinaNew York$464K
- Michele BiscossiSaratoga Springs$64K
- Heidi YipCanandaigua$29K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Ann HarrisBrooklyn$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.